Cargando…
Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience
Clinical data of patients with severe aplastic anemia (SAA) were retrospectively analyzed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (HID-HSCT) with matched related sibling hematopoietic stem cell transplantation (MSD-HSCT) in complications and survivals. Thir...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820587/ https://www.ncbi.nlm.nih.gov/pubmed/35141252 http://dx.doi.org/10.3389/fmed.2021.807527 |
_version_ | 1784646234308345856 |
---|---|
author | Wang, QingYun Ren, HanYun Liang, ZeYin Liu, Wei Yin, Yue Wang, QingYa Wang, Qian Sun, YuHua Xu, WeiLin Qiu, ZhiXiang Ou, JinPing Han, Na Wang, Jing Dong, YuJun Li, Yuan |
author_facet | Wang, QingYun Ren, HanYun Liang, ZeYin Liu, Wei Yin, Yue Wang, QingYa Wang, Qian Sun, YuHua Xu, WeiLin Qiu, ZhiXiang Ou, JinPing Han, Na Wang, Jing Dong, YuJun Li, Yuan |
author_sort | Wang, QingYun |
collection | PubMed |
description | Clinical data of patients with severe aplastic anemia (SAA) were retrospectively analyzed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (HID-HSCT) with matched related sibling hematopoietic stem cell transplantation (MSD-HSCT) in complications and survivals. Thirty consecutive patients were enrolled in the study with a median follow-up of 50 months (range 4, 141), and the median age of the patients was 21 years (range 3, 49). All the patients achieved myeloid engraftment in the two cohorts. The cumulative incidences of platelet engraftment were 95.5 and 100% in HID cohort and MSD cohort, respectively. The median time for neutrophil and platelet recovery was 11 (range 9, 19) and 15 (range 10, 25) days in HID cohort, and 12 (range 10, 19) and 14 (range 8, 25) days in MSD cohort. The cumulative incidences of grade II–IV and grade III–IV acute graft vs. host disease (aGvHD) in HID cohort and in MSD cohort were 18.9 vs. 14.3% (p = 0.77) and 10.5 vs. 0% (p = 0.42), respectively. The cumulative incidences of chronic graft vs. host disease (cGvHD) was 22.7% in HID cohort and 25.5% in MSD cohort (p = 0.868). The 5-year overall survival (OS) rates and 5-year failure-free survival (FFS) rates in HID cohort and MSD cohort were 85.1 vs. 87.5% (p = 0.858), 80.3 vs. 87.5% (p = 0.635), respectively. The median time to achieve engraftment, cumulative incidence of aGvHD and cGvHD, and the 5-year OS and FFS rates were not significantly different between the two cohorts. We suggest that HID-HSCT might be a safety and effective option for SAA patients without a matched donor. |
format | Online Article Text |
id | pubmed-8820587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88205872022-02-08 Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience Wang, QingYun Ren, HanYun Liang, ZeYin Liu, Wei Yin, Yue Wang, QingYa Wang, Qian Sun, YuHua Xu, WeiLin Qiu, ZhiXiang Ou, JinPing Han, Na Wang, Jing Dong, YuJun Li, Yuan Front Med (Lausanne) Medicine Clinical data of patients with severe aplastic anemia (SAA) were retrospectively analyzed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (HID-HSCT) with matched related sibling hematopoietic stem cell transplantation (MSD-HSCT) in complications and survivals. Thirty consecutive patients were enrolled in the study with a median follow-up of 50 months (range 4, 141), and the median age of the patients was 21 years (range 3, 49). All the patients achieved myeloid engraftment in the two cohorts. The cumulative incidences of platelet engraftment were 95.5 and 100% in HID cohort and MSD cohort, respectively. The median time for neutrophil and platelet recovery was 11 (range 9, 19) and 15 (range 10, 25) days in HID cohort, and 12 (range 10, 19) and 14 (range 8, 25) days in MSD cohort. The cumulative incidences of grade II–IV and grade III–IV acute graft vs. host disease (aGvHD) in HID cohort and in MSD cohort were 18.9 vs. 14.3% (p = 0.77) and 10.5 vs. 0% (p = 0.42), respectively. The cumulative incidences of chronic graft vs. host disease (cGvHD) was 22.7% in HID cohort and 25.5% in MSD cohort (p = 0.868). The 5-year overall survival (OS) rates and 5-year failure-free survival (FFS) rates in HID cohort and MSD cohort were 85.1 vs. 87.5% (p = 0.858), 80.3 vs. 87.5% (p = 0.635), respectively. The median time to achieve engraftment, cumulative incidence of aGvHD and cGvHD, and the 5-year OS and FFS rates were not significantly different between the two cohorts. We suggest that HID-HSCT might be a safety and effective option for SAA patients without a matched donor. Frontiers Media S.A. 2022-01-24 /pmc/articles/PMC8820587/ /pubmed/35141252 http://dx.doi.org/10.3389/fmed.2021.807527 Text en Copyright © 2022 Wang, Ren, Liang, Liu, Yin, Wang, Wang, Sun, Xu, Qiu, Ou, Han, Wang, Dong and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Wang, QingYun Ren, HanYun Liang, ZeYin Liu, Wei Yin, Yue Wang, QingYa Wang, Qian Sun, YuHua Xu, WeiLin Qiu, ZhiXiang Ou, JinPing Han, Na Wang, Jing Dong, YuJun Li, Yuan Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience |
title | Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience |
title_full | Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience |
title_fullStr | Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience |
title_full_unstemmed | Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience |
title_short | Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience |
title_sort | comparable outcomes in acquired severe aplastic anemia patients with haploidentical donor or matched related donor transplantation: a retrospective single-center experience |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820587/ https://www.ncbi.nlm.nih.gov/pubmed/35141252 http://dx.doi.org/10.3389/fmed.2021.807527 |
work_keys_str_mv | AT wangqingyun comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT renhanyun comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT liangzeyin comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT liuwei comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT yinyue comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT wangqingya comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT wangqian comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT sunyuhua comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT xuweilin comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT qiuzhixiang comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT oujinping comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT hanna comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT wangjing comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT dongyujun comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience AT liyuan comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience |